Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CY6032 aficamten vs metoprolol in symptomatic obstructive hypertrophic cardiomyopathy
2023-504809-37-00Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of aficamten in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Cytokinetics. Primary endpoint: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing. Started Dec 2023; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2023-504809-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504809-37-00.